SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Elon Musks warning that tighter debt markets could trigger failures and consolidation among AI neoclouds has fueled concern about Nebiuss capital-intensive expansion and weighed on sentiment. Bulls counter that Nebius has secured financing and customer commitments, arguing it is better positioned than weaker sector peers; others remain concerned about debt access and execution risks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

Elon Musks warning that many neocloud operators could fail or consolidate, alongside concerns about debt-heavy AI data-center expansion and tighter financing, is driving attention to IREN and its peers. Traders debate whether the comments amplify genuine funding and execution risks or are self-interested criticism, with bulls pointing to IRENs contracts and infrastructure while bears warn of further losses.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas positive Phase 3 melanoma-vaccine results with Mercks Keytruda have driven discussion, but shares sold off as traders judged the data against heightened expectations and questioned the treatments commercial potential. Bulls view the results as validation for a broader cancer-vaccine platform, while skeptics point to approval, adoption and profitability uncertainties and await evidence in other cancers.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Brazils presidential election has driven sharp swings in Brazilian stocks, including NU, as traders react to political and economic uncertainty. The community is split between viewing the selloff as a buying opportunity and waiting for the stock to stabilize, with some arguing the companys fundamentals remain strong.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs event-driven Phase 3 REGAL trial of its GPS leukemia vaccine dominates discussion, with traders focused on the final analysis triggered at 80 survival events and anticipating a possible data update around ASH. Bulls speculate the prolonged wait could reflect a survival benefit, while skeptics question the delay, the companys quiet period, and whether the blinded trial will ultimately succeed; SLS009 updates are a secondary catalyst.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Lulas election victory after markets had positioned for a Bolsonaro win prompted a sharp selloff in Brazilian shares, including Petrobras. Traders are divided between concerns about political and dividend risks under Lula and the view that the decline is an overreaction given Petrobras oil business and valuation.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

EWZ is drawing attention after Brazils unexpected Lula victory triggered a sharp selloff, as traders worry about political and economic uncertainty and the markets apparent positioning for a Bolsonaro win. Many are bearish on Brazils outlook, while others argue the decline is an overreaction and see a potential buying opportunity.

XP, Inc. engages in the operation of technology-driven financial services platform. The firm provides customers with two principal types of offerings, financial advisory services for retail clients in Brazil, high-net-worth clients, international clients and corporate and institutional clients, and an open financial product platform providing access to over 800 investment products including equity and fixed income securities, mutual and hedge funds, structured products, life insurance, pension plans, real-estate investment funds (REITs) and others from XP, its partners and competitors. he company was founded by Guilherme Dias Fernandes Benchimol in 2001 and is headquartered in Vila Olimpia, Brazil.

XP Inc - Ordinary Shares - Class A

XP Inc. is trending as investors react to a new capital optimization plan, which includes a significant buyback program and planned dividend distributions, while the community remains divided over the firm's long-term growth prospects and the broader volatility of Brazilian financial stocks. Discussion is heavily focused on whether these capital return initiatives can stabilize the share price following a multi-year downtrend and ongoing skepticism regarding the company's reliance on specific high-volatility financial products.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCelleras ABCL635 clinical results for menopausal hot flashesand its presentation of additional Phase 1/2 safety and patient-reported dataare the dominant focus, alongside anticipation for further durability data. The reaction is largely bullish on the program and its potential, while some traders caution that expectations may be high and the stock could consolidate or sell off without stronger new evidence.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

Biotech is pulling back after a recent sector rally, with traders debating whether the weakness is a pause or a broader deterioration. IBBs hold near its 50-day moving average is cited as support, while some see large-cap biotech holding up better than smaller names.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AFRM Stock Hits 11-Month High – Affirm CEO Says Over 30% Growth Shows “No Signs Of Slowing Down”

Equity

In an interview with CNBC, Affirm CEO Max Levchin said higher interest rates would have a limited impact on Affirm’s business and funding model.


ITOT, XOM, WMT, LRCX: ETF Inflow Alert

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $242.7 million dollar inflow -- that's a 0.3% i...

IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval

PEMGARDA’s emergency status will end on June 29, 2027, unless the company secures full FDA approval in the meantime.


Trump Says $800M Will Be Invested In Stock Market This Week For American Children As Trump Accounts Go Live

Addressing reporters at the White House, the U.S. President said that these Trump Accounts are being funded using seed money from the United States government and contributions from individuals.

NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema

Nektar Therapeutics has multiple near-term catalysts in place, some expected as early as this month.


BLK Stock Gains After-Hours — US Treasury To Offer Two BlackRock ETFs As Options In Trump Accounts

The U.S. Treasury has selected two low-cost BlackRock iShares exchange-traded funds as foundational investment options for the upcoming federal "Trump Accounts" initiative to build childhood wealth.

iShares and SPDR ETFs Offer Similar Exposure With Different Scale

Key PointsState Street SPDR Portfolio S&P 1500 Composite Stock Market ETF and iShares Core S&P Total U.S. Stock Market ETF share identical 0.03% expense ratios...

Which Is the Better ETF, the iShares Total Market ITOT or Vanguard's Value-Oriented VTV?

Key PointsThe iShares Core S&P Total U.S. Stock Market ETF provides exposure to the entire domestic market with a significant technology tilt, whereas the Vanguard Value ETF focuses on undervalued large-cap stocks...

Is the iShares Core S&P Total U.S. Stock Market ETF the Best Broad Market Fund?

Key PointsThe Schwab U.S. Broad Market ETF and the iShares Core S&P Total U.S. Stock Market ETF both offer an identical 0.03% expense ratio and 1.0% dividend yield...

Big Tech's $635B AI Push Meets Energy Crunch: ETFs to Diversify 

Rising oil prices threaten to derail Big Tech's massive AI push. Staying diversified with ETFs may be the smartest long-term move.

iShares Trust - iShares Core S&P Total U.S. Stock Market ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Levchin said Affirm’s long-term funding relationships and staggered maturities help cushion the company from short-term Fed rate moves.</li><li>He added Affirm has maintained “sustained profitable growth” while expanding more than 30% annually.</li><li>According to him, “the Affirm consumer is healthy” despite persistent inflation and higher gasoline prices.</li></ul>Affirm Holdings (AFRM) rallied to an 11-month high in morning trade on Friday before paring some of the gains after its quarterly earnings beat, with CEO Max Levchin saying the buy-now, pay-later company has grown more than 30% for 11 straight quarters and is showing “no signs of slowing down.”“I think we’ve grown for 30-plus percent for the last 11 straight quarters and showed no signs of slowing down,” Levchin said in an interview with CNBC following Affirm’s latest earnings report. “I think we’ll be here for all economies.”Affirm reported fiscal fourth-quarter revenue of about $1.16 billion, up 33% year over year, and ahead of the $1.11 consensus estimate, as per Koyfin. The company also delivered its most profitable quarter to date, according to management.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260828_094143728_e413986d99.png" alt="koyfin_20260828_094143728.png" width="2400" height="1240"><figcaption>AFRM stock single-day gains over the past two years on August 28 as of 9:35 a.m. ET | Source: Koyfin</figcaption></figure><a href="https://stocktwits.com/symbol/AFRM">AFRM stock</a> climbed nearly 13% in morning trade, to levels last seen in September 2025, and was on track to log its biggest single-day jump since May 2025.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260828_093909564_b0bb1c01df.png" alt="koyfin_20260828_093909564.png" width="2400" height="1240"><figcaption>AFRM stock price performance over the past 12 months on August 28 as of 9:35 a.m. ET | Source: Koyfin</figcaption></figure><h2 class="st-heading-2">Affirm CEO Says Higher Rates Haven’t Disrupted Funding</h2>Levchin said Affirm sees demand in different economic conditions for different reasons. During periods of inflation, consumers may become more deliberate about how they spend and use installment payments to manage larger purchases. When economic growth is stronger, consumers may turn to Affirm for more discretionary spending.“We very successfully lived through the last round of rates going up,” Levchin said, stating that Affirm's results showed relatively little impact from higher rates.He added that the company's funding arrangements mean its ability to operate is “really not impacted all that much in the short term” when the Federal Reserve moves rates. Over the longer term, he said, Affirm plans its funding structure carefully.Levchin noted that Affirm has maintained “sustained profitable growth” while expanding more than 30% annually and that the “the Affirm customer is healthy,” despite persistent inflation and higher gasoline prices.<h2 class="st-heading-2">How Is Retail Feeling About AFRM Stock?</h2>AFRM stock was also among the top trending tickers on Stocktwits at the time of writing. Retail sentiment around Affirm rose to ‘extremely bullish’ from ‘bullish’ over the past day, and chatter climbed to ‘extremely high’ from ‘normal’ levels.&nbsp;One retail trader pointed to Affirm’s technical setup and suggested the stock could move into the low-$90s.<stembedurl>https://stocktwits.com/Dr_Stoxx/message/663092427</stembedurl>Another trader took a more aggressive view, predicting a gain of more than 20% in the session following Affirm’s “huge beat.”<stembedurl>https://stocktwits.com/Profafa/message/663053768</stembedurl>AFRM’s stock has gained nearly 20% this year and around 11% in the last 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-12-trillion-valuation-raymond-james-supply-constraints/cZYo4liRJqf">NVDA Stock Posts Biggest Jump In 14 Months On $12 Trillion Valuation Call From Raymond James – ‘Supply Is The Primary Constraint’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, a person holds a smartphone displaying the logo of Affirm Holdings, Inc. 

In an interview with CNBC, Affirm CEO Max Levchin said higher interest rates would have a limited impact on Affirm’s business and funding model.

Affirm CEO Says Company Will Be ‘Here For All Economies’ After 11 Straight Quarters Of Over 30% Growth 

Affirm Holdings Inc

iShares Core S&P Total U.S. Stock Market ETF

Corgi ETF Trust I. - Corgi Buy Now Pay Later ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

ITOT iShares Core S&P Total U.S. Stock Market ETF

Fundamentals

Latest ITOT News